Everything we've seen

1. ?Nov 13, 7:30 PMdecisionconsidered

   Agent 4 — Dip Buyer (Frozen) — decide: skip

   MRNA is down 20.5% from its 30-day high with no available news headlines explaining the drop, and SEC filings lack extracted financial metrics, making it difficult to pinpoint a specific deterioration catalyst. Moderna remains a fundamentally active biotech with ongoing mRNA pipeline development, though it has faced persistent revenue headwinds as COVID vaccine demand has normalized. The macro environment shows a flattening yield curve (T10Y2Y at 0.24, 2.0σ below trend), which is modestly risk-off and not particularly supportive for high-beta, speculative biotech names like MRNA.

2. !Nov 13, 7:30 PMsignalseverity 0.20

   Agent 4 — Dip Buyer (Frozen) — dip_skipped

   MRNA is down 20.5% from its 30-day high with no available news headlines explaining the drop, and SEC filings lack extracted financial metrics, making it difficult to pinpoint a specific deterioration catalyst. Moderna remains a fundamentally active biotech with ongoing mRNA pipeline development, though it has faced persistent revenue headwinds as COVID vaccine demand has normalized. The macro environment shows a flattening yield curve (T10Y2Y at 0.24, 2.0σ below trend), which is modestly risk-off and not particularly supportive for high-beta, speculative biotech names like MRNA.

3. ?Nov 13, 3:30 PMdecisionconsidered

   Agent 7 — Day Trader — decide: skip

   With only 15 minutes remaining until the forced close, the window for meaningful continuation is extremely tight. MRNA has already moved -3.05%, which is a significant intraday decline and represents real selling pressure. However, the critical factor here is time: 15 minutes is insufficient for the move to extend another meaningful leg toward the +3% profit target, and late-session dynamics often include profit-taking by shorts, covering, and mean-reversion flows. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is more relevant to defensives and banks than biotech/MRNA specifically, providing no directional tailwind for continuation. No supporting headlines to explain or sustain the selloff. With the position needing to be flattened at 3:45 PM ET anyway, the risk/reward of chasing a -3% move in the final 15 minutes is poor — the probability of capturing the remaining downside before EOD flatten is low relative to the risk of a late-day snap-back squeeze. Probability below 0.5 warranted by time constraint alone.

4. !Nov 13, 3:30 PMsignalseverity -0.03

   Agent 7 — Day Trader — day_trade_skipped

   With only 15 minutes remaining until the forced close, the window for meaningful continuation is extremely tight. MRNA has already moved -3.05%, which is a significant intraday decline and represents real selling pressure. However, the critical factor here is time: 15 minutes is insufficient for the move to extend another meaningful leg toward the +3% profit target, and late-session dynamics often include profit-taking by shorts, covering, and mean-reversion flows. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is more relevant to defensives and banks than biotech/MRNA specifically, providing no directional tailwind for continuation. No supporting headlines to explain or sustain the selloff. With the position needing to be flattened at 3:45 PM ET anyway, the risk/reward of chasing a -3% move in the final 15 minutes is poor — the probability of capturing the remaining downside before EOD flatten is low relative to the risk of a late-day snap-back squeeze. Probability below 0.5 warranted by time constraint alone.

5. ?Nov 13, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

6. !Nov 13, 3:20 PMsignalseverity 0.20

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

7. ?Nov 13, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

8. !Nov 13, 3:20 PMsignalseverity 0.20

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

9. ?Nov 13, 2:21 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

10. !Nov 13, 2:21 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

11. ?Nov 13, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

12. !Nov 13, 2:21 PMsignalseverity 0.20

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

13. ?Nov 13, 1:56 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 3.74% intraday with no headline catalyst visible, suggesting this is likely flow/positioning-driven selling rather than a news event that might reverse quickly. A move of this magnitude reflects real conviction from sellers. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly supportive of defensive rotation away from high-beta biotech names like MRNA, which could sustain selling pressure. No reversal signal is evident — no mention of a fade off lows or recovery attempt. With 110 minutes remaining there is meaningful time for continuation toward the close. However, MRNA is a volatile single-name biotech prone to intraday whipsaws, and without volume data or a clear catalyst confirming sustained institutional selling, confidence is moderate rather than high. No strong counter-thesis presents itself, so the default lean per the system framework is mild continuation probability just above threshold.

14. !Nov 13, 1:56 PMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 3.74% intraday with no headline catalyst visible, suggesting this is likely flow/positioning-driven selling rather than a news event that might reverse quickly. A move of this magnitude reflects real conviction from sellers. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening signal) is modestly supportive of defensive rotation away from high-beta biotech names like MRNA, which could sustain selling pressure. No reversal signal is evident — no mention of a fade off lows or recovery attempt. With 110 minutes remaining there is meaningful time for continuation toward the close. However, MRNA is a volatile single-name biotech prone to intraday whipsaws, and without volume data or a clear catalyst confirming sustained institutional selling, confidence is moderate rather than high. No strong counter-thesis presents itself, so the default lean per the system framework is mild continuation probability just above threshold.

15. ?Nov 13, 1:23 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

16. !Nov 13, 1:23 PMsignalseverity 0.20

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    The 20.3% drop from the 30-day high does qualify as a meaningful mean-reversion candidate, and the Health Care sector is showing strong relative strength (+13.91pts vs SPY over 30 days), suggesting this dip may be stock-specific rather than sector-wide — a negative idiosyncratic signal. The evidence stack is thin: no insider buying, no options flow, no news headlines, and no macro brief to contextualize the move. The 10Y yield at 4.98% is a meaningful headwind for a growth/duration-sensitive biotech name like MRNA, and VIX at the 69th percentile adds moderate market uncertainty. Net signal score: the drop magnitude earns +1, no earnings within 30 days earns +1, but high 10Y yield (-1), sector outperforming while this stock is idiosyncratically down (-1), and no confirming signals (zero insider, zero options flow) leaves the net score at 0 — marginal at best. For re-entry, the prior exit was at $187.04 and price is now at $223.72 — a full recovery well above that level — but there is no identifiable fundamental catalyst or fresh evidence supporting a new thesis. Re-entry without grounding in new evidence is discouraged per framework guidelines.

17. ?Nov 13, 1:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

18. !Nov 13, 1:23 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

19. ?Nov 13, 12:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down ~2.09% intraday with no headline catalyst visible, suggesting this is flow/technical driven rather than news-driven. The move is meaningful but not extreme. Macro context shows a flattening yield curve (T10Y2Y at 2.0σ below trend), which is modestly risk-off and could provide slight tailwind for continued selling in a growth/biotech name like MRNA. With 205 minutes remaining there is ample time for continuation or reversal. No reversal signals are evident from the data provided. The absence of news does not disqualify the momentum thesis. Overall, slight lean toward continuation given the risk-off macro backdrop and meaningful move size, but conviction is modest — probability just above the 0.5 threshold.

20. !Nov 13, 12:20 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down ~2.09% intraday with no headline catalyst visible, suggesting this is flow/technical driven rather than news-driven. The move is meaningful but not extreme. Macro context shows a flattening yield curve (T10Y2Y at 2.0σ below trend), which is modestly risk-off and could provide slight tailwind for continued selling in a growth/biotech name like MRNA. With 205 minutes remaining there is ample time for continuation or reversal. No reversal signals are evident from the data provided. The absence of news does not disqualify the momentum thesis. Overall, slight lean toward continuation given the risk-off macro backdrop and meaningful move size, but conviction is modest — probability just above the 0.5 threshold.

21. ?Nov 13, 11:36 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

22. !Nov 13, 11:36 AMsignalseverity 0.19

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $227.51, suggesting underlying demand, but the 19% drop from the 30-day high of $280.80 is notable without any explanatory headlines or confirmed catalyst. The SEC filings (10-Q for Q3 2026) have empty metrics, leaving fundamentals opaque, and there are no insider purchases, no unusual options flow, and no news catalysts to anchor a bullish thesis. Health Care (XLV) is the second-strongest sector on 30d relative strength (+13.91pts vs SPY), suggesting the dip is at least partially idiosyncratic to MRNA rather than a sector-wide selloff — which warrants some caution. The re-entry context shows the stock has well surpassed the prior exit price, but without grounded evidence of a new fundamental driver, this recovery appears more like mean reversion.

23. ?Nov 13, 10:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 1.68% with no attributable news catalyst, suggesting either broad biotech/risk-off selling or idiosyncratic flow. The move is meaningful but sub-2%, which is moderate rather than strong conviction. Macro context shows T10Y2Y at 2.0σ below trend — a flatter/inverted-leaning curve environment is not particularly hostile to biotech/growth names (more a bank headwind), so macro doesn't add meaningful tailwind or headwind here. With 310 minutes remaining (over 5 hours), there is ample time for continuation or reversal, so time is neutral-to-supportive for continuation. No news means no catalyst clarity in either direction. The move lacks the magnitude or macro alignment to confidently assign high continuation probability, but the system's bounded risk profile and the absence of a clear reversal signal (no fade off highs described, no volume anomaly flagged) keeps this at the minimum threshold. Assigning 0.50 — baseline momentum continuation with no strong reason to fade.

24. !Nov 13, 10:35 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 1.68% with no attributable news catalyst, suggesting either broad biotech/risk-off selling or idiosyncratic flow. The move is meaningful but sub-2%, which is moderate rather than strong conviction. Macro context shows T10Y2Y at 2.0σ below trend — a flatter/inverted-leaning curve environment is not particularly hostile to biotech/growth names (more a bank headwind), so macro doesn't add meaningful tailwind or headwind here. With 310 minutes remaining (over 5 hours), there is ample time for continuation or reversal, so time is neutral-to-supportive for continuation. No news means no catalyst clarity in either direction. The move lacks the magnitude or macro alignment to confidently assign high continuation probability, but the system's bounded risk profile and the absence of a clear reversal signal (no fade off highs described, no volume anomaly flagged) keeps this at the minimum threshold. Assigning 0.50 — baseline momentum continuation with no strong reason to fade.

25. ?Nov 12, 7:30 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MRNA is down 17.6% from its 30-day high, but there are no news headlines or SEC filing metrics available to identify a specific negative catalyst driving the decline. The 10-Q filed for the period ending 2026-09-30 contains no extractable metrics, making fundamental assessment difficult, though the absence of alarming headlines suggests no acute deterioration. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but MRNA as a biotech/mRNA platform company is highly sensitive to pipeline news and revenue concentration risk, which cannot be ruled out without more data.

26. !Nov 12, 7:30 PMsignalseverity 0.18

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    MRNA is down 17.6% from its 30-day high, but there are no news headlines or SEC filing metrics available to identify a specific negative catalyst driving the decline. The 10-Q filed for the period ending 2026-09-30 contains no extractable metrics, making fundamental assessment difficult, though the absence of alarming headlines suggests no acute deterioration. The macro backdrop shows inflation expectations (T10YIE at 2.2, 1.7σ below trend) that are benign for equities broadly, but MRNA as a biotech/mRNA platform company is highly sensitive to pipeline news and revenue concentration risk, which cannot be ruled out without more data.

27. ?Nov 12, 2:36 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has dropped 15.2% from its 30-day high, meeting the magnitude threshold for a mean-reversion candidate, and the Health Care sector is showing strong relative strength (+12.56pts vs SPY over 30 days), which is a positive sector tailwind. However, the evidence stack is thin: no news headlines, no insider activity, no options flow data, and SEC filings contain no extractable metrics — meaning we cannot assess whether the drop has a fundamental cause or is pure noise. The re-entry context is relevant here: the prior stop-out at $187.04 (itself well above the $144.73 entry) and the current price of $238.20 represent a significant re-entry premium of ~27% above the last exit, with no grounding evidence (new catalysts, earnings beat, pipeline news) to justify renewed conviction. The recovery from $187 to $238 appears to be unrelated mean reversion rather than a thesis-driven re-rating.

28. !Nov 12, 2:36 PMsignalseverity 0.17

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has dropped 15.2% from its 30-day high, meeting the magnitude threshold for a mean-reversion candidate, and the Health Care sector is showing strong relative strength (+12.56pts vs SPY over 30 days), which is a positive sector tailwind. However, the evidence stack is thin: no news headlines, no insider activity, no options flow data, and SEC filings contain no extractable metrics — meaning we cannot assess whether the drop has a fundamental cause or is pure noise. The re-entry context is relevant here: the prior stop-out at $187.04 (itself well above the $144.73 entry) and the current price of $238.20 represent a significant re-entry premium of ~27% above the last exit, with no grounding evidence (new catalysts, earnings beat, pipeline news) to justify renewed conviction. The recovery from $187 to $238 appears to be unrelated mean reversion rather than a thesis-driven re-rating.

29. ?Nov 12, 2:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 6.81% with 70 minutes remaining — a substantial move that represents real institutional flow. No headlines are available to explain the drop, but absence of news is not a disqualifier; large biotech moves frequently precede or accompany off-channel catalyst discovery. The macro context (T10YIE at 2.2, 1.7σ below trend) reflects falling inflation expectations, which is modestly supportive of long-duration/growth assets like biotech — this slightly argues against further downside continuation but is not a strong countervailing force for a single-name idiosyncratic move of this magnitude. With 70 minutes left, there is meaningful time for continuation selling or additional distribution. However, a ~7% intraday decline in a high-beta biotech with no visible catalyst raises the possibility that the move is exhausting — late-session mean reversion or short covering is plausible. No clear reversal signal is visible from the data provided. On balance, the base rate for large-move continuation into the close, combined with ample remaining session time, nudges probability just above the 0.5 threshold, but not convincingly. Assigning modest continuation probability to the downside.

30. !Nov 12, 2:35 PMsignalseverity -0.07

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 6.81% with 70 minutes remaining — a substantial move that represents real institutional flow. No headlines are available to explain the drop, but absence of news is not a disqualifier; large biotech moves frequently precede or accompany off-channel catalyst discovery. The macro context (T10YIE at 2.2, 1.7σ below trend) reflects falling inflation expectations, which is modestly supportive of long-duration/growth assets like biotech — this slightly argues against further downside continuation but is not a strong countervailing force for a single-name idiosyncratic move of this magnitude. With 70 minutes left, there is meaningful time for continuation selling or additional distribution. However, a ~7% intraday decline in a high-beta biotech with no visible catalyst raises the possibility that the move is exhausting — late-session mean reversion or short covering is plausible. No clear reversal signal is visible from the data provided. On balance, the base rate for large-move continuation into the close, combined with ample remaining session time, nudges probability just above the 0.5 threshold, but not convincingly. Assigning modest continuation probability to the downside.

31. ?Nov 12, 1:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 2.52% today with no attributable headline catalyst, suggesting this is likely technical or flow-driven selling. The move is meaningful in magnitude and represents real conviction from whoever initiated it. With 145 minutes remaining there is ample time for continuation. The macro context (T10YIE at 1.7σ below 24-month trend) reflects a low inflation expectations environment, which is modestly favorable for growth/biotech names like MRNA — this creates a slight headwind to continuation of the downside move, as the sector backdrop is not overtly bearish. No news to amplify the move, no clear reversal signal either. With no strong reason to expect a fade and reasonable time remaining, the base case is mild continuation of downward momentum, though conviction is low. Assigning 0.52 — just above the trigger threshold — reflecting ordinary momentum with no strong countervailing signal to reverse.

32. !Nov 12, 1:20 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 2.52% today with no attributable headline catalyst, suggesting this is likely technical or flow-driven selling. The move is meaningful in magnitude and represents real conviction from whoever initiated it. With 145 minutes remaining there is ample time for continuation. The macro context (T10YIE at 1.7σ below 24-month trend) reflects a low inflation expectations environment, which is modestly favorable for growth/biotech names like MRNA — this creates a slight headwind to continuation of the downside move, as the sector backdrop is not overtly bearish. No news to amplify the move, no clear reversal signal either. With no strong reason to expect a fade and reasonable time remaining, the base case is mild continuation of downward momentum, though conviction is low. Assigning 0.52 — just above the trigger threshold — reflecting ordinary momentum with no strong countervailing signal to reverse.

33. ?Nov 12, 11:06 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 3.74% today with no headlines to explain the move, suggesting either institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The absence of news is not a disqualifier — this represents real flow. Macro context shows T10YIE at 1.7σ below trend (2.2%), indicating compressed inflation expectations, which is modestly supportive of growth/biotech names on a rates basis but not strongly so. With 280 minutes remaining (nearly a full session still ahead), there is ample time for the move to continue or extend. No reversal signals are evident from the data provided. The move is meaningful in magnitude (nearly 4%), crossing a psychologically significant threshold. However, without volume confirmation data or a clear catalyst, conviction is moderate rather than high. The asymmetric risk/reward of the system (tight -1.5% stop vs. +3% target) supports taking the trade on a modest continuation read. Probability set at 0.52 — lean continuation on size-driven momentum with no reversal signal, but held below 0.6 due to lack of volume data, no news catalyst, and the biotech sector's historically mean-reverting intraday behavior on down days without fundamental drivers.

34. !Nov 12, 11:06 AMsignalseverity -0.04

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 3.74% today with no headlines to explain the move, suggesting either institutional selling or sector rotation rather than a news-driven spike that might quickly reverse. The absence of news is not a disqualifier — this represents real flow. Macro context shows T10YIE at 1.7σ below trend (2.2%), indicating compressed inflation expectations, which is modestly supportive of growth/biotech names on a rates basis but not strongly so. With 280 minutes remaining (nearly a full session still ahead), there is ample time for the move to continue or extend. No reversal signals are evident from the data provided. The move is meaningful in magnitude (nearly 4%), crossing a psychologically significant threshold. However, without volume confirmation data or a clear catalyst, conviction is moderate rather than high. The asymmetric risk/reward of the system (tight -1.5% stop vs. +3% target) supports taking the trade on a modest continuation read. Probability set at 0.52 — lean continuation on size-driven momentum with no reversal signal, but held below 0.6 due to lack of volume data, no news catalyst, and the biotech sector's historically mean-reverting intraday behavior on down days without fundamental drivers.

35. ?Nov 12, 10:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has dropped 15.2% from its 30-day high to $238.20, but the evidence base is thin: no news headlines, no insider buying, no options flow, and SEC filings with empty metrics — leaving the cause of the drop undiagnosed. The Health Care sector (XLV) is a strong relative outperformer (+12.56pts vs SPY over 30 days), suggesting this is an idiosyncratic drop rather than sector-wide pressure, which warrants caution. The re-entry context is notable: the prior trade was exited at $187.04 (a profitable stop-out), and the stock has since rallied ~27% to $238.20 without identifiable fundamental grounding in the evidence provided, making re-entry at this elevated level speculative.

36. !Nov 12, 10:20 AMsignalseverity 0.15

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has dropped 15.2% from its 30-day high to $238.20, but the evidence base is thin: no news headlines, no insider buying, no options flow, and SEC filings with empty metrics — leaving the cause of the drop undiagnosed. The Health Care sector (XLV) is a strong relative outperformer (+12.56pts vs SPY over 30 days), suggesting this is an idiosyncratic drop rather than sector-wide pressure, which warrants caution. The re-entry context is notable: the prior trade was exited at $187.04 (a profitable stop-out), and the stock has since rallied ~27% to $238.20 without identifiable fundamental grounding in the evidence provided, making re-entry at this elevated level speculative.

37. ?Nov 12, 10:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has dropped 15.2% from its 30-day high, meeting the magnitude threshold for a mean-reversion candidate, and the Health Care sector is showing strong relative strength (+12.56pts vs SPY over 30 days), which is a positive sector tailwind. However, the evidence stack is thin: no news headlines, no insider activity, no options flow data, and SEC filings contain no extractable metrics — meaning we cannot assess whether the drop has a fundamental cause or is pure noise. The re-entry context is relevant here: the prior stop-out at $187.04 (itself well above the $144.73 entry) and the current price of $238.20 represent a significant re-entry premium of ~27% above the last exit, with no grounding evidence (new catalysts, earnings beat, pipeline news) to justify renewed conviction. The recovery from $187 to $238 appears to be unrelated mean reversion rather than a thesis-driven re-rating.

38. !Nov 12, 10:20 AMsignalseverity 0.15

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has dropped 15.2% from its 30-day high, meeting the magnitude threshold for a mean-reversion candidate, and the Health Care sector is showing strong relative strength (+12.56pts vs SPY over 30 days), which is a positive sector tailwind. However, the evidence stack is thin: no news headlines, no insider activity, no options flow data, and SEC filings contain no extractable metrics — meaning we cannot assess whether the drop has a fundamental cause or is pure noise. The re-entry context is relevant here: the prior stop-out at $187.04 (itself well above the $144.73 entry) and the current price of $238.20 represent a significant re-entry premium of ~27% above the last exit, with no grounding evidence (new catalysts, earnings beat, pipeline news) to justify renewed conviction. The recovery from $187 to $238 appears to be unrelated mean reversion rather than a thesis-driven re-rating.

39. ?Nov 12, 9:50 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 3.20% with ~355 minutes remaining — substantial time for continuation but also for mean reversion. No headlines are present to explain the move, which suggests either quiet selling pressure or a catalyst not yet captured. The macro backdrop (T10YIE at 1.7σ below trend) reflects a falling inflation expectations environment, which is modestly supportive of risk assets generally but doesn't strongly favor biotech/growth names like MRNA in either direction. A 3.2% move is meaningful and represents real institutional flow, lending some credence to momentum continuation. However, with no news catalyst to anchor the narrative and no clear sector-level pressure from macro, there's elevated risk of intraday fade as the session matures. The move is not extreme enough to suggest panic or capitulation that would typically accelerate into the close. Net assessment: modest downside continuation probability — the momentum earns a slight edge but conviction is low without a clear driver.

40. !Nov 12, 9:50 AMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    MRNA is down 3.20% with ~355 minutes remaining — substantial time for continuation but also for mean reversion. No headlines are present to explain the move, which suggests either quiet selling pressure or a catalyst not yet captured. The macro backdrop (T10YIE at 1.7σ below trend) reflects a falling inflation expectations environment, which is modestly supportive of risk assets generally but doesn't strongly favor biotech/growth names like MRNA in either direction. A 3.2% move is meaningful and represents real institutional flow, lending some credence to momentum continuation. However, with no news catalyst to anchor the narrative and no clear sector-level pressure from macro, there's elevated risk of intraday fade as the session matures. The move is not extreme enough to suggest panic or capitulation that would typically accelerate into the close. Net assessment: modest downside continuation probability — the momentum earns a slight edge but conviction is low without a clear driver.

41. ?Nov 12, 9:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

42. ?Nov 12, 9:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

43. !Nov 12, 9:20 AMsignalseverity 0.11

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

44. !Nov 12, 9:20 AMsignalseverity 0.11

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

45. ?Nov 11, 7:31 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MRNA is down 10.7% from its 30-day high, a moderate drawdown with no company-specific negative news headlines in the window and no adverse metrics surfacing in the SEC filings (8-K and 10-Q filed 2026-11-06 show empty metrics, suggesting no dramatic disclosed deterioration). However, the macro context is a mild headwind: the fed funds rate is running 2.0σ above its 24-month trend at 3.88%, which pressures growth/biotech valuations via higher discount rates. Without catalysts or clear positive momentum signals, and given MRNA's historically high volatility and ongoing revenue normalization post-COVID, a full rebound to the 30-day high within 90 days is roughly a coin-flip but slightly below threshold.

46. !Nov 11, 7:31 PMsignalseverity 0.11

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    MRNA is down 10.7% from its 30-day high, a moderate drawdown with no company-specific negative news headlines in the window and no adverse metrics surfacing in the SEC filings (8-K and 10-Q filed 2026-11-06 show empty metrics, suggesting no dramatic disclosed deterioration). However, the macro context is a mild headwind: the fed funds rate is running 2.0σ above its 24-month trend at 3.88%, which pressures growth/biotech valuations via higher discount rates. Without catalysts or clear positive momentum signals, and given MRNA's historically high volatility and ongoing revenue normalization post-COVID, a full rebound to the 30-day high within 90 days is roughly a coin-flip but slightly below threshold.

47. ?Nov 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

48. !Nov 11, 2:21 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

49. ?Nov 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

50. !Nov 11, 2:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

51. ?Nov 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

52. !Nov 11, 1:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

53. ?Nov 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

54. !Nov 11, 1:20 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

55. ?Nov 11, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

56. !Nov 11, 12:20 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

57. ?Nov 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

58. !Nov 11, 12:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

59. ?Nov 11, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

60. ?Nov 11, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

61. !Nov 11, 10:21 AMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

62. ?Nov 11, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, but no evidence in the filing metrics, news, insider activity, or options flow explains the basis of that recovery or the current 10.7% dip. The 10-Q filed 2026-11-06 contains no extractable metrics, making fundamental soundness unverifiable. Health Care sector is a relative bright spot (rank 3/11, +12.51pts vs SPY over 30 days), which means this dip is more idiosyncratic to MRNA than sector-driven — a negative signal. Without a cluster insider buy, unusual call flow, or any identifiable catalyst to justify re-entry above the prior exit price, the evidence stack is too thin to confidently underwrite the thesis.

63. ?Nov 11, 9:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    MRNA has recovered substantially from the prior stop-out at $187.04 to $250.83, suggesting meaningful positive momentum over the past 42 days. However, the evidence base is thin: SEC filings lack financial metrics, there are no news headlines, no insider activity, and no options flow to confirm the recovery is fundamentals-driven. The Health Care sector is a strong relative outperformer (rank 3 of 11, +12.51pts vs SPY over 30 days), suggesting the dip may be a sector-level pullback rather than idiosyncratic deterioration, which is modestly constructive. The 10.7% drop from the 30-day high in an outperforming sector suggests mean-reversion potential.

64. ?Nov 10, 7:31 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MRNA is down 10.7% from its 30-day high, a moderate drawdown with no company-specific negative news headlines in the window and no adverse metrics surfacing in the SEC filings (8-K and 10-Q filed 2026-11-06 show empty metrics, suggesting no dramatic disclosed deterioration). However, the macro context is a mild headwind: the fed funds rate is running 2.0σ above its 24-month trend at 3.88%, which pressures growth/biotech valuations via higher discount rates. Without catalysts or clear positive momentum signals, and given MRNA's historically high volatility and ongoing revenue normalization post-COVID, a full rebound to the 30-day high within 90 days is roughly a coin-flip but slightly below threshold.

65. ?Nov 10, 12:16 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 5.11% with 210 minutes remaining — a meaningful move with substantial time left in the session. The magnitude of the decline suggests real institutional selling pressure, not noise. No headlines are available, but absence of news does not disqualify continuation; large biotech moves frequently occur on options flow, sector rotation, or institutional repositioning without immediate public catalysts. The macro context (DFF elevated 2.0σ above trend at 3.88%) reflects a relatively tight monetary environment, which is modestly negative for high-multiple, speculative biotech names like MRNA that are sensitive to discount rates. With 210 minutes remaining there is ample time for continuation or recovery, but no reversal signal is evident. The setup is a plain momentum continuation read — no strong tailwinds to reverse the move, no catalyst for a snap-back. Probability set modestly above 0.5 to reflect: (1) meaningful decline already established, (2) ample time remaining, (3) rate-sensitive sector headwind, offset by (4) absence of a news driver that could sustain a second leg lower with conviction.

66. ?Nov 10, 10:55 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is down 3.84% with 290 minutes remaining — a meaningful move with substantial time left in the session. No headlines are available to explain the drop, but absence of news doesn't disqualify the move; large institutional flows often precede or occur without immediate public catalysts in biotech names. The macro context (DFF 2σ above trend) reflects a tighter-than-expected rate environment, which is modestly negative for high-multiple growth/biotech names like MRNA that are sensitive to discount rate assumptions. With nearly 5 hours remaining, there is ample time for the move to extend, and the initial 3.84% drop suggests real selling conviction. However, without a clear catalyst or volume confirmation data, and given that MRNA has already absorbed a notable decline that could attract dip buyers intraday, the continuation probability is moderate rather than high. No reversal pattern is evident from the data provided. Overall, slight lean toward continuation of the downside move into the close, but not a high-conviction setup.

67. ?Nov 4, 9:20 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto fires immediately: earnings are imminent in 7 days (2026-11-04), and the override conditions are not met — there is no insider cluster buy (only a single insider, the President, executing large scheduled sales totaling ~$17M across two days, a clear negative signal), and options flow shows a bearish skew with a put/call ratio of 1.31. The consensus EPS is -$1.22, confirming Moderna remains in a loss-generating phase. Additionally, the insider selling is clustered and large, adding a -1 signal on top of the earnings veto. The 10Y yield at 5.00% is a structural headwind for a duration-sensitive biotech burning cash. While Health Care is the top-ranked sector by 30d relative strength (+5.25pts vs SPY), the single-stock drop is idiosyncratic rather than sector-wide, adding another -1 signal.

68. ?Nov 4, 9:20 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The single most dominant factor here is imminent earnings — MRNA reports tomorrow (2026-11-04, BMO) with a consensus EPS of -$1.22, making this a high-binary-risk event that nearly mandates a skip per the scoring framework. The stock has already recovered significantly from the prior stop-out level ($187 → $228), meaning the easy mean-reversion trade is behind us, not ahead. Sector health care is actually outperforming strongly (rank 2/11, +12pts vs SPY in 30d), which means MRNA's 10.3% dip is idiosyncratic — a red flag suggesting company-specific negative pressure rather than a sector-wide pullback that will naturally reverse. The options P/C ratio of 0.70 is modestly bullish but not unusually so, and there are no insider buys, no analyst upgrades, and no 8-K metrics to anchor a fundamental thesis.

69. ?Nov 3, 2:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The single most dominant factor here is imminent earnings — MRNA reports tomorrow (2026-11-04, BMO) with a consensus EPS of -$1.22, making this a high-binary-risk event that nearly mandates a skip per the scoring framework. The stock has already recovered significantly from the prior stop-out level ($187 → $228), meaning the easy mean-reversion trade is behind us, not ahead. Sector health care is actually outperforming strongly (rank 2/11, +12pts vs SPY in 30d), which means MRNA's 10.3% dip is idiosyncratic — a red flag suggesting company-specific negative pressure rather than a sector-wide pullback that will naturally reverse. The options P/C ratio of 0.70 is modestly bullish but not unusually so, and there are no insider buys, no analyst upgrades, and no 8-K metrics to anchor a fundamental thesis.

70. ?Nov 3, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto fires immediately: earnings are imminent in 7 days (2026-11-04), and the override conditions are not met — there is no insider cluster buy (only a single insider, the President, executing large scheduled sales totaling ~$17M across two days, a clear negative signal), and options flow shows a bearish skew with a put/call ratio of 1.31. The consensus EPS is -$1.22, confirming Moderna remains in a loss-generating phase. Additionally, the insider selling is clustered and large, adding a -1 signal on top of the earnings veto. The 10Y yield at 5.00% is a structural headwind for a duration-sensitive biotech burning cash. While Health Care is the top-ranked sector by 30d relative strength (+5.25pts vs SPY), the single-stock drop is idiosyncratic rather than sector-wide, adding another -1 signal.

71. ?Nov 3, 2:20 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is up 3.59% with 85 minutes remaining — a meaningful intraday move suggesting real institutional flow. No headlines are available to explain the catalyst, but absence of news does not negate the momentum signal; size moved this stock and that conviction often persists into the close. However, several factors temper enthusiasm: (1) The macro context shows the Fed funds rate running 2.2σ above its 24-month trend, reflecting a tighter-than-expected rate environment that generally pressures growth/biotech names like MRNA by raising the discount rate on future cash flows — a mild headwind to continuation. (2) At 3.59%, the move is approaching the upper end of the 2-5% range where profit-taking and mean-reversion become more likely, especially without a clear catalyst to sustain the narrative. (3) With 85 minutes left, there is reasonable time for the move to extend, but also enough time for late-session fading if early buyers take profits. On balance, momentum is modestly favored to continue but without strong conviction — this is a borderline setup. Probability is set just above the 0.5 threshold to capture asymmetric upside given the system's bounded risk profile.

72. ?Nov 3, 11:16 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is up ~4.87% today with no attributable headline, suggesting this is flow-driven — likely institutional positioning or options-related activity. The move is meaningful in magnitude and represents real conviction from whoever initiated it. However, several factors temper enthusiasm: (1) No news catalyst means the move may lack a durable narrative to attract additional buyers into the close; (2) 270 minutes remaining is actually a full session — this is early-to-mid session, so there is ample time but also ample time for reversal; (3) The macro context (elevated DFF at 2.2σ above trend) is modestly unfavorable for growth/biotech names like MRNA, as tighter-than-expected monetary conditions historically compress multiples in speculative healthcare; (4) A ~5% move without news in biotech can attract profit-taking, particularly as the session matures. On balance, with no strong reason to fade and the system's bounded risk profile (1.5% stop, 3% target), the base case leans toward continuation but with modest conviction. No reversal pattern is evident, and the move has size behind it.

73. ?Nov 3, 9:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    MRNA is up 4.30% with 370 minutes remaining — essentially a full session still ahead, which is ample time for continuation. The move is meaningful in magnitude, suggesting real institutional flow rather than noise. However, there are no supporting headlines to explain the catalyst, which limits conviction on whether the move has further fundamental justification or is more likely to fade as intraday momentum exhausts. The macro context (elevated DFF at 2.2σ above trend) is modestly negative for risk assets broadly but MRNA as a biotech is not directly rate-sensitive in the short term. No reversal signals are present. With no clear reason to fade the move but also no strong catalyst to sustain it, this is an ordinary momentum read — assigning modest continuation probability above threshold.

74. ?Nov 2, 5:01 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    MRNA is down 13.2% from its 30-day high with no available news headlines or detailed SEC financial metrics to explain the drop, suggesting the decline may be technical or sentiment-driven rather than fundamental. The two recent 8-K filings lack financial metrics, providing no evidence of material adverse events. However, Moderna operates in a volatile biotech/vaccine space with historically wide price swings, and the macro context (elevated mortgage rates, no clear broad-market tailwind described) does not provide a particularly supportive backdrop for a near-term rebound.

75. ?Nov 2, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The most significant near-term risk is imminent earnings in 7 days (2026-11-04, before market open), with a consensus EPS of -$1.22, which by default leans toward a skip absent unusually strong countervailing evidence. Insider activity is a clear negative signal: MRNA's President Stephen Hoge executed large sales (~$17M combined) on 10/14–10/15, a meaningful directional negative on a dipping stock. Options flow tilts bearish with a P/C ratio of 1.31 (more puts than calls), offering no confirmation of informed buying. The stock is dipping while Health Care ranks #1 in sector relative strength over 30 days, suggesting this is an idiosyncratic, company-specific decline rather than sector-wide pressure — demanding a clearer fundamental catalyst for recovery that is absent from available evidence. No headlines, no 10-K/10-Q filings with substantive metrics, and no insider cluster buys provide the evidence needed to support re-entry.

76. ?Nov 2, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto fires immediately: earnings are imminent in 7 days (2026-11-04), and the override conditions are not met — there is no insider cluster buy (only a single insider, the President, executing large scheduled sales totaling ~$17M across two days, a clear negative signal), and options flow shows a bearish skew with a put/call ratio of 1.31. The consensus EPS is -$1.22, confirming Moderna remains in a loss-generating phase. Additionally, the insider selling is clustered and large, adding a -1 signal on top of the earnings veto. The 10Y yield at 5.00% is a structural headwind for a duration-sensitive biotech burning cash. While Health Care is the top-ranked sector by 30d relative strength (+5.25pts vs SPY), the single-stock drop is idiosyncratic rather than sector-wide, adding another -1 signal.

77. ?Nov 2, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The most significant near-term risk is imminent earnings in 7 days (2026-11-04, before market open), with a consensus EPS of -$1.22, which by default leans toward a skip absent unusually strong countervailing evidence. Insider activity is a clear negative signal: MRNA's President Stephen Hoge executed large sales (~$17M combined) on 10/14–10/15, a meaningful directional negative on a dipping stock. Options flow tilts bearish with a P/C ratio of 1.31 (more puts than calls), offering no confirmation of informed buying. The stock is dipping while Health Care ranks #1 in sector relative strength over 30 days, suggesting this is an idiosyncratic, company-specific decline rather than sector-wide pressure — demanding a clearer fundamental catalyst for recovery that is absent from available evidence. No headlines, no 10-K/10-Q filings with substantive metrics, and no insider cluster buys provide the evidence needed to support re-entry.

78. ?Nov 2, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto fires immediately: earnings are imminent in 7 days (2026-11-04), and the override conditions are not met — there is no insider cluster buy (only a single insider, the President, executing large scheduled sales totaling ~$17M across two days, a clear negative signal), and options flow shows a bearish skew with a put/call ratio of 1.31. The consensus EPS is -$1.22, confirming Moderna remains in a loss-generating phase. Additionally, the insider selling is clustered and large, adding a -1 signal on top of the earnings veto. The 10Y yield at 5.00% is a structural headwind for a duration-sensitive biotech burning cash. While Health Care is the top-ranked sector by 30d relative strength (+5.25pts vs SPY), the single-stock drop is idiosyncratic rather than sector-wide, adding another -1 signal.

79. ?Nov 2, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    The most significant near-term risk is imminent earnings in 7 days (2026-11-04, before market open), with a consensus EPS of -$1.22, which by default leans toward a skip absent unusually strong countervailing evidence. Insider activity is a clear negative signal: MRNA's President Stephen Hoge executed large sales (~$17M combined) on 10/14–10/15, a meaningful directional negative on a dipping stock. Options flow tilts bearish with a P/C ratio of 1.31 (more puts than calls), offering no confirmation of informed buying. The stock is dipping while Health Care ranks #1 in sector relative strength over 30 days, suggesting this is an idiosyncratic, company-specific decline rather than sector-wide pressure — demanding a clearer fundamental catalyst for recovery that is absent from available evidence. No headlines, no 10-K/10-Q filings with substantive metrics, and no insider cluster buys provide the evidence needed to support re-entry.

80. ?Nov 2, 9:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    A hard veto fires immediately: earnings are imminent in 7 days (2026-11-04), and the override conditions are not met — there is no insider cluster buy (only a single insider, the President, executing large scheduled sales totaling ~$17M across two days, a clear negative signal), and options flow shows a bearish skew with a put/call ratio of 1.31. The consensus EPS is -$1.22, confirming Moderna remains in a loss-generating phase. Additionally, the insider selling is clustered and large, adding a -1 signal on top of the earnings veto. The 10Y yield at 5.00% is a structural headwind for a duration-sensitive biotech burning cash. While Health Care is the top-ranked sector by 30d relative strength (+5.25pts vs SPY), the single-stock drop is idiosyncratic rather than sector-wide, adding another -1 signal.

81. ❖Sep 30, 10:35 AMnewsvia finnhub

    Wednesday's session: gap up and gap down stock in the S&P500 index

    Stay updated with the S&P500 gap up and gap down stocks on Wednesday. Get a glimpse of the market's movement during today's session.

82. ❖Sep 30, 9:42 AMnewsvia finnhub

    Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay Flat

    Citigroup just slapped a Sell rating on one of 2026's most explosive biotech stocks, warning that soaring investor hopes around a cancer vaccine partnership with Merck have carried the valuation into dangerous territory.

83. ❖Sep 30, 9:41 AMnewsvia finnhub

    Tech leads stocks higher after cooler-than-expected inflation read: AlphaCheck

    Here's the market action in the first few minutes of trading.

84. ❖Sep 30, 9:40 AMnewsvia finnhub

    Target upgraded, Moderna downgraded: Wall Street's top analyst calls

    Target upgraded, Moderna downgraded: Wall Street's top analyst calls

85. ❖Sep 30, 8:35 AMnewsvia finnhub

    These S&P500 stocks are moving in today's pre-market session

    Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics.

86. ❖Sep 30, 8:28 AMnewsvia finnhub

    Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.

    Citi downgrades Moderna to Sell from Hold, saying the data around its cancer vaccine, instimeran autogene, isn’t enough to justify the valuation.

87. ❖Sep 30, 8:03 AMnewsvia finnhub

    MRNA Stock Falls Premarket After Citi Downgrade: Analyst Says Valuation Looks Stretched Despite Cancer Vaccine Momentum

    Citi downgraded Moderna to 'Sell' on valuation concerns after a massive 2026 rally, while investors await detailed Phase 3 melanoma data at ESMO next month.

88. ❖Sep 30, 8:02 AMnewsvia finnhub

    Here Are Wednesday’s Top Wall Street Analyst Research Calls: Ally Financial, BankUnited, Ciena Corporation, CoreWeave, Dow, FormFactor, Lumentum Holdings, Moderna, Target, and More

    Rising Treasury yields are rattling markets heading into the final trading day of Q3, and Wall Street analysts are making bold moves on a wide range of stocks from big-box retail to AI infrastructure. Find out who got cut and who got a fresh vote of confidence.

89. ❖Sep 30, 8:02 AMnewsvia finnhub

    Premarket movers: Micron; Boeing rises, Moderna slides

    Investing.com - U.S. stock index futures hovered around the flatline on Wednesday, as investors turned their focus to key inflation data closely watched by the Federal Reserve and upcoming earnings from semiconductor group Micron.

90. ❖Sep 30, 7:16 AMnewsvia finnhub

    9 Stocks Turn $100,000 to $18.8 Million In 9 Months

    September turned out to be a mediocre month for S&P 500 investors. But some stocks wound up having a great month.

91. ❖Sep 30, 7:00 AMnewsvia finnhub

    Moderna Adds Chief Operating Officer Role as Company Expands into Oncology

    Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at ModernaCAMBRIDGE, MA / ACCESS Newswire / September 30, 2026 / (NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and diversification of the Company.The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader onco

92. ❖Sep 30, 4:54 AMnewsvia finnhub

    This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

    Analysts downgraded SoundThinking, Moderna, Accelerant, Mobileye and Dow, revising their ratings and price targets.

93. ❖Sep 30, 4:22 AMnewsvia finnhub

    Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

    Analysts revised targets and ratings for KMX, ARX, JKHY, MRNA, GO, HNGE, AYTU and MSFT, with mixed upgrades, downgrades and reiterations.

94. ❖Sep 30, 4:02 AMnewsvia finnhub

    Concentrix Posts Mixed Q3 Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

    Concentrix plunged 10.6% premarket after weak guidance, despite an earnings beat; several other stocks also traded lower.

95. ▣Sep 29, 8:00 PMjournaltarget

    Agent 5 — Dip Buyer (Evolving) closed long 7 @ $187.04 (+$296.19)

    Trailing stop on remainder: close $187.04 ≤ floor $189.22 (peak $203.46 × 0.93; floor at entry $144.73)

96. ▣Sep 29, 8:00 PMjournaltarget

    Agent 8 — Dip Buyer (Peer-Aware) closed long 11 @ $187.04 (+$504.78)

    Trailing stop on remainder: close $187.04 ≤ floor $189.22 (peak $203.46 × 0.93; floor at entry $141.15)

97. ❖Sep 29, 10:24 AMnewsvia finnhub

    2 S&P 500 Stocks to Consider Right Now and 1 We Question

    While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

98. ❖Sep 29, 8:25 AMnewsvia finnhub

    Moderna And Merck: The Intismeran Readout That Was Worth $86 Billion

    Moderna (MRNA) valuation update: stock near bull-case range but central-case implies downside.

99. ❖Sep 29, 3:05 AMnewsvia finnhub

    Wall Street Breakfast Podcast: Federal Boost For Navitas

    A new U.S. government award has Navitas shares surging. After a string of acquisitions, Lilly is hunting for its next big bet. A judge keeps a high-stakes mRNA patent battle alive.

100. ❖Sep 29, 2:30 AMnewsvia finnhub

     ValuEngine Weekly Commentary: Sector And ETF Performance

     U.S. equity markets were mixed this week, with technology and growth-related areas leading, while several defensive and rate-sensitive sectors moved lower. Read more here...

101. ❖Sep 28, 10:48 AMnewsvia finnhub

     Up Over 550% in 2026, Is It Too Late to Buy Moderna Stock?

     Positive news surrounding its personalized cancer vaccine has lit a fire under the healthcare stock.

102. ❖Sep 28, 8:35 AMnewsvia finnhub

     These S&P500 stocks that are showing activity before the opening bell on Monday.

     Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.

103. ❖Sep 28, 3:59 AMnewsvia finnhub

     MRNA Stock Eyes Best Year Ever: Analyst Calls China’s AI Drug Lead ‘Baseless’ As Moderna Awaits Cancer Data

     Laidlaw analyst Yale Jen flagged possible data in other cancers from 2027, while warning that personalized manufacturing costs, capacity and reimbursement could limit commercial success.

104. ❖Sep 28, 12:47 AMnewsvia finnhub

     Why Did AMD, HPE, MRNA Stocks Surge To 52-Week Highs Last Week?

     Investors rewarded companies with strong artificial intelligence demand, enterprise infrastructure, and drug development.

105. ❖Sep 26, 9:11 PMnewsvia finnhub

     Why Moderna (MRNA) Is Up 29.1% After Melanoma Vaccine Success And Middle East Expansion Talks

     In recent weeks, Moderna and Merck reported that their Phase 3 INTerpath-001 trial of personalized cancer vaccine intismeran autogene plus Keytruda met its primary endpoint in melanoma, with full data presented earlier this month at the European Society for Medical Oncology Congress 2026 and accompanied by growing oncology-focused pipeline visibility. At the same time, Moderna’s talks with Middle East partners about potential investment and manufacturing cooperation highlight how its mRNA...

106. ❖Sep 26, 8:11 PMnewsvia finnhub

     Moderna (MRNA) Held Investment Talks With The UAE Government

     Moderna (NasdaqGS:MRNA) entered high-level investment talks with the UAE government on advanced pharmaceutical manufacturing and R&D collaboration. The discussions focus on expanded research capabilities, potential local production, and broader access to Middle Eastern healthcare markets. Management framed the UAE engagement as part of a wider push to build out Moderna's international footprint beyond existing Western partnerships. The UAE collaboration talks matter, but investors also need...

107. ❖Sep 26, 4:25 AMnewsvia finnhub

     What Moved Markets This Week

     U.S. stocks advanced for the week while Treasury yields surged and petroleum markets remained in focus. Read more about this week's major events on Wall Street.

108. ❖Sep 25, 4:50 PMnewsvia finnhub

     Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

     Moderna (MRNA) concluded the recent trading session at $198.88, signifying a +2.08% move from its prior day's close.

109. ❖Sep 25, 2:37 PMnewsvia finnhub

     MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today?

     Fresh analyst commentary put the spotlight on Moderna’s expanding mRNA cancer pipeline and Precigen’s transition into a commercial-stage biotech following the FDA approval of Papzimeos.

110. ❖Sep 25, 12:40 PMnewsvia finnhub

     Stock Market Midday, Sept. 25: AI Momentum Lifts Markets as Akamai Soars on Anthropic Deal

     Dow, Nasdaq, and S&P 500 all gain ground despite climbing bond yields, with AI stocks leading the charge, today, Sept. 25, 2026.

111. ❖Sep 25, 12:02 PMnewsvia finnhub

     AMD Hits $1 Trillion, Muse Spooks Subscription Stocks: This Week on Wall Street

     AMD crossed $1 trillion and Meta's Muse rattled subscription stocks. Meanwhile, Treasury yields hit 2007 highs.

112. ❖Sep 25, 11:39 AMnewsvia finnhub

     Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts.

     Biotechnology stocks are soaring this year as medical advances and merger activity rekindle investor interest. More gains lie ahead, our healthcare panel says.

113. ❖Sep 25, 7:47 AMnewsvia finnhub

     Moderna Stock Reached New 52-Week High: What's Happening?

     Moderna Inc. (NASDAQ: MRNA) shares are trading higher Friday, hitting a fresh 52-week high on anticipation of clinical trial data.

114. ❖Sep 25, 1:07 AMnewsvia finnhub

     Moderna Stock Jumped 7% Thursday. The Real Test Comes at ESMO on October 24.

     Key TakeawaysOncology Repricing: Moderna stock jumped 7% on Thursday, September 24, closing at $195 as investors kept betting on intismeran autogene’s Phase 3 melanoma data due at ESMO on October 24. Street Split: The 23 analysts covering Moderna stock are split 4 buys, 1 outperform, 16 holds, 1 underperform, and 1 sell, with a mean target of $120 that sits 39% below Thursday’s close.

115. ❖Sep 24, 11:23 PMnewsvia finnhub

     MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

     Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

116. ❖Sep 24, 8:46 PMnewsvia finnhub

     Moderna Inc. (MRNA) Holds High-Level Investment Talks With UAE, Soars to 4-Year Peak

     Moderna Inc. (NASDAQ:MRNA) saw its share price climb to a new four-year high on Thursday, as investors cheered news that it was exploring investment opportunities in the Middle East. In intra-day trading, the stock climbed to a record high of $195.71 before trimming gains to finish the session just up by 6.98 percent at $194.82 […]

117. ❖Sep 24, 6:54 PMnewsvia finnhub

     Why is Moderna (MRNA) Stock Trending After Hours?

     Moderna shares rose 0.09% after hours Thursday as investors eyed upcoming oncology data at a major European conference.

118. ❖Sep 24, 6:41 PMnewsvia finnhub

     From $63 To $195: Moderna’s Two-Month Rerating Isn’t Done

     The stock was most recently helped by the company CEO’s optimism on its potential outside of COVID vaccines.

119. ❖Sep 24, 3:05 PMnewsvia finnhub

     Discover which S&P500 stocks are making waves on Thursday.

     Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

120. ❖Sep 24, 11:56 AMnewsvia finnhub

     Moderna's View of the Global Pharma Industry

     Chief executive Stéphane Bancel shares what’s next for Moderna after its report of a breakthrough of its cancer vaccine. He also discusses the state of the FDA and competition from China, AI integration in the drug industry and bioterrorism readiness.

121. ❖Sep 23, 11:52 PMnewsvia finnhub

     Why Did META, MRNA, OKTA Stocks Surge To 52-Week Highs Today?

     Meta Platforms, Moderna and Okta rallied to fresh 52-week highs on Wednesday amid positive company catalysts and improving investor sentiment.

122. ▢Sep 23, 8:00 PMjournal

     Agent 7 — Day Trader opened long 15 @ $186.97

123. ▣Sep 23, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 15 @ $181.74 (-$78.37)

     Long stop: close $181.74 ≤ stop $184.16

124. ❖Sep 23, 2:00 PMnewsvia finnhub

     Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines

     Moderna stock heads for its highest close since 2023 after CEO Stéphane Bancel says the drugmaker ‘has never been’ just a Covid vaccine company.

125. ❖Sep 23, 1:54 PMnewsvia finnhub

     These 2 Stocks Are Bucking The Broader Market Selloff To Hit New Multi-Year Highs — Here’s What’s Driving The Enthusiasm

     Moderna and Twilio climbed to multi-year highs on Wednesday, fueled by optimism around Moderna’s broader mRNA pipeline and Twilio’s emerging opportunity from the rapid adoption of AI agents.

126. ❖Sep 23, 11:02 AMnewsvia finnhub

     Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID

     Moderna (NASDAQ:MRNA) executives emphasized the company’s evolution beyond COVID-19 vaccines during a discussion with Bernstein, highlighting its mRNA platform, personalized cancer vaccine program intismeran, rare-disease pipeline and plans to expand therapeutics development. Chief Executive Office

127. ❖Sep 23, 9:35 AMnewsvia finnhub

     10 Health Care Stocks Whale Activity In Today’s Session

     This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

128. ❖Sep 23, 8:39 AMnewsvia finnhub

     Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

     Moderna, Inc. (MRNA) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 8:50 AM EDTCompany...

129. ❖Sep 23, 8:28 AMnewsvia finnhub

     6 ‘Moonshot’ Biotech Stocks That Offer Big Risks, Bigger Rewards

     Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

130. ❖Sep 23, 7:42 AMnewsvia finnhub

     Analysts Think 6 S&P 500 Stocks Are Grossly Overvalued

     There's a joke on Wall Street that analysts never saw an S&P 500 stock they didn't like. Well, that doesn't seem to be the case now.

131. ❖Sep 23, 6:02 AMnewsvia finnhub

     TriSalus Life Sciences, Lakefront Biotherapeutics, Editas Medicine And Other Big Stocks Moving Higher On Wednesday

     U.S. stocks fell as Nasdaq dropped 100+ points, while TriSalus surged 5.8% on FDA clearance; Securitize, Lakefront and others also gained.

132. ❖Sep 23, 1:45 AMnewsvia finnhub

     These ‘Moonshot’ Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.

     Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.

133. ❖Sep 23, 12:33 AMnewsvia finnhub

     Moderna (MRNA) Tied To AI Drug Push As Bob Langer Takes New Advisory Role

     Moderna (NasdaqGS:MRNA) co-founder Bob Langer has joined the scientific advisory board of Cellular Intelligence, a biotech focused on AI-driven drug development. The appointment aligns with Cellular Intelligence's recent acquisition of a Parkinson's cell therapy program, linking AI discovery with advanced neurology research. Langer's role connects Moderna's mRNA expertise with a growing network of AI medicine collaborations involving Cellular Intelligence and its new Parkinson's therapy...

134. ❖Sep 22, 10:12 PMnewsvia finnhub

     Moderna (MRNA) Stock Looks Very Expensive As Shares Surge Over 1 Year

     Moderna has delivered a very large 1 year share price gain, which puts fresh attention on a basic question. Is the current valuation of the stock supported by the company’s sales profile rather than just recent momentum and headlines? The stock is up a very large amount over the past 12 months, which makes the link between Moderna’s market value and its underlying sales more important for anyone thinking about valuation risk. News around mRNA products, from the mFlusiva flu vaccine launch to...

135. ▣Sep 21, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 11 @ $179.83 (+$425.47)

     Staged exit (1/2.0): close $179.83 ≥ target $176.66. Selling 11/22 sh, trailing remainder.

136. ▣Sep 21, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 6 @ $179.83 (+$210.62)

     Staged exit (1/2.0): close $179.83 ≥ target $176.66. Selling 6/13 sh, trailing remainder.

137. ▢Sep 21, 8:00 PMjournal

     Agent 7 — Day Trader opened long 16 @ $181.31

138. ▣Sep 21, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 16 @ $183.04 (+$27.68)

     EOD forced close — day trader never carries overnight

139. ▢Sep 20, 8:00 PMjournal

     Agent 7 — Day Trader opened long 18 @ $163.23

140. ▣Sep 20, 8:00 PMjournaltarget

     Agent 7 — Day Trader closed long 18 @ $168.42 (+$93.42)

     Long target: close $168.42 ≥ target $168.13

141. ▢Aug 31, 8:00 PMjournal

     Agent 7 — Day Trader opened long 19 @ $147.66

142. ▣Aug 31, 8:00 PMjournaltarget

     Agent 7 — Day Trader closed long 19 @ $152.77 (+$97.09)

     Long target: close $152.77 ≥ target $152.09

143. ▢Aug 27, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 11 @ $141.15

144. ▢Aug 27, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 11 @ $141.15

145. ▣Aug 26, 8:00 PMjournalstop

     Agent 8 — Dip Buyer (Peer-Aware) closed long 7 @ $145.18 (-$95.44)

     intraday stop sweep

146. ▢Aug 24, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 7 @ $158.82

147. ▢Aug 23, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 6 @ $144.73

148. ▢Aug 23, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 7 @ $144.73

149. ▣Jun 28, 8:00 PMjournaltarget

     Agent 20 — SIR Price/Volume closed long 31 @ $69.70 (+$443.92)

     Target hit: close $69.70 ≥ target $66.46

150. ▣Jun 21, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 29 @ $59.35 (+$303.10)

     Trailing stop on remainder: close $59.34 ≤ floor $59.48 (peak $63.96 × 0.93; floor at entry $48.89)

151. ▣Jun 21, 8:00 PMjournalstop

     options_momentum closed long 70 @ $10.29 (+$440.79)

     Stop: premium $10.29 ≤ trailing floor $10.86 (peak $14.49 × 0.75)

152. ▣Jun 16, 8:00 PMjournaltarget

     Agent 5 — Dip Buyer (Evolving) closed long 28 @ $61.77 (+$360.63)

     Staged exit (1/2.0): close $61.77 ≥ target $59.48. Selling 28/57 sh, trailing remainder.

153. ▢Jun 15, 8:00 PMjournal

     Agent 7 — Day Trader opened long 55 @ $53.52

154. ▣Jun 15, 8:00 PMjournaltarget

     Agent 7 — Day Trader closed long 55 @ $55.33 (+$99.55)

     Long target: close $55.33 ≥ target $55.13

155. ▣Jun 15, 8:00 PMjournaltarget

     options_momentum closed long 30 @ $8.18 (+$125.69)

     De-risk: premium $8.18 ≥ 2.0× entry $3.99. Selling 30/100 contracts; trailing the remainder.

156. ▢Jun 15, 8:00 PMjournal

     Agent 20 — SIR Price/Volume opened long 31 @ $55.38

157. ▢Jun 11, 8:00 PMjournal

     options_momentum opened long 30 @ $3.99

158. ▢Jun 11, 8:00 PMjournal

     options_momentum opened long 70 @ $3.99

159. ▣Jun 10, 8:00 PMjournalstop

     options_momentum closed long 100 @ $2.52 (-$66.31)

     Stop: premium $2.52 ≤ trailing floor $2.61 (peak $3.48 × 0.75)

160. ▢Jun 9, 8:00 PMjournal

     options_momentum opened long 100 @ $3.18

161. ▣Jun 7, 8:00 PMjournalstop

     options_momentum closed long 100 @ $2.03 (-$205.79)

     Stop: premium $2.03 ≤ trailing floor $3.07 (peak $4.09 × 0.75)

162. ▢Jun 3, 8:00 PMjournal

     options_momentum opened long 100 @ $4.09

163. ▣Jun 2, 8:00 PMjournalstop

     options_momentum closed long 200 @ $2.14 (-$247.70)

     Stop: premium $2.14 ≤ trailing floor $2.79 (peak $3.71 × 0.75)

164. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 28 @ $48.89

165. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 29 @ $48.89

166. ▢May 21, 8:00 PMjournal

     options_momentum opened long 200 @ $3.38

167. ▣May 20, 8:00 PMjournalstop

     options_momentum closed long 200 @ $3.21 (-$22.63)

     Stop: premium $3.21 ≤ trailing floor $3.39 (peak $4.53 × 0.75)

168. ▢May 18, 8:00 PMjournal

     options_momentum opened long 200 @ $3.32